Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

Clemens M. WendtnerKlinikum Schwabing, Academic Teaching Hospital of University of Munich, Munich, Germany; ;Department I of Internal Medicine, University of Cologne, Cologne, Germany; Correspondence[email protected]

Michael HallekDepartment I of Internal Medicine, University of Cologne, Cologne, Germany; ;Cologne Cluster of Excellence in Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany;

Graeme A. M. FraserJuravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada;

Anne-Sophie MichalletHospices Civils De Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France;

Peter HillmenSt James’s Institute of Oncology, Leeds, UK;

Jan DürigUniversity Hospital Essen, Essen, Germany;

Matt KalaycioCleveland Clinic, Cleveland, OH, USA;

John G. GribbenBarts Cancer Institute, Queen Mary, University of London, London, UK;

Stephan StilgenbauerDepartment of Internal Medicine III, Ulm University, Ulm, Germany;

Andreas BuhlerDepartment of Internal Medicine III, Ulm University, Ulm, Germany;

Thomas J. KippsUniversity of California San Diego Moores Cancer Center, La Jolla, CA, USA;

Brendan PurseCelgene Corporation, Summit, NJ, USA;

Jennie ZhangCelgene Corporation, Summit, NJ, USA;

Sabine De BedoutCelgene Corporation, Boudry, Switzerland;

Jay MeiCelgene Corporation, Summit, NJ, USA;

Asher Chanan-KhanMayo Clinic, Jacksonville, FL, USACorrespondence[email protected]

show all

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date